| Prev Close | 9.34 |
| Open | 9.35 |
| Day Low/High | 9.14 / 9.42 |
| 52 Wk Low/High | 4.83 / 23.59 |
| Volume | 100.08K |
| Avg Volume | 247.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 47.12M |
| Market Cap | 440.08M |
| EPS | -2.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Karyopharm Therapeutics Stock Sees Short Interest Increase 13.3%
The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 351,835 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,991,079, an increase of 13.33% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Karyopharm Doses First Patient In Pivotal Phase 3 BOSTON Study Evaluating Selinexor In Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Projected To Be Complete in 2018; Top-Line Data Expected in 2019
Karyopharm's Phase 2b SADAL Data Evaluating Selinexor In Diffuse Large B-Cell Lymphoma Selected For Oral Presentation At The 2017 European Hematology Association Annual Meeting
Phase 2b SADAL Data Also Selected for Poster Presentation at ICML 2017
RSI Alert: Karyopharm Therapeutics (KPTI) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Karyopharm To Report First Quarter 2017 Financial Results On May 4, 2017
Conference Call Scheduled for Thursday, May 4, 2017 at 8:30 a.m. ET
Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 15% Annualized Using Options
Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 65 cents.
Six Stocks Spiking Up With Huge Volume
Here's a technical look at how to play six stocks trending higher with strong volume.
Short Interest Makes 14.6% Move For KPTI
The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 316,239 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,483,391, an increase of 14.59% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Karyopharm And Medidata Expand Clinical Trial Partnership
Medidata (NASDAQ:MDSO) and clinical-stage pharmaceutical company Karyopharm Therapeutics (NASDAQ:KPTI) today announced an expanded partnership to bring novel machine-learning technology and targeted risk-based monitoring...
Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017
Conference Call Scheduled for Thursday, March 16, 2017 at 8:30 a.m. ET
Biotech Premarket Movers: Karyopharm, Lexicon, Prothena
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Commit To Buy Karyopharm Therapeutics At $7.50, Earn 19.6% Annualized Using Options
Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $10.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $7.50 strike, which has a bid at the time of this writing of 85 cents.
